EP0723460A4 - Therapie genique concernant le systeme nerveux - Google Patents

Therapie genique concernant le systeme nerveux

Info

Publication number
EP0723460A4
EP0723460A4 EP94930498A EP94930498A EP0723460A4 EP 0723460 A4 EP0723460 A4 EP 0723460A4 EP 94930498 A EP94930498 A EP 94930498A EP 94930498 A EP94930498 A EP 94930498A EP 0723460 A4 EP0723460 A4 EP 0723460A4
Authority
EP
European Patent Office
Prior art keywords
nervous system
gene therapy
therapy
gene
nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94930498A
Other languages
German (de)
English (en)
Other versions
EP0723460A1 (fr
Inventor
Zvi Ram
R Michael Blaese
Edward H Oldfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of EP0723460A1 publication Critical patent/EP0723460A1/fr
Publication of EP0723460A4 publication Critical patent/EP0723460A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP94930498A 1993-10-01 1994-09-28 Therapie genique concernant le systeme nerveux Withdrawn EP0723460A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13108593A 1993-10-01 1993-10-01
US131085 1993-10-01
PCT/US1994/010977 WO1995009654A1 (fr) 1993-10-01 1994-09-28 Therapie genique concernant le systeme nerveux

Publications (2)

Publication Number Publication Date
EP0723460A1 EP0723460A1 (fr) 1996-07-31
EP0723460A4 true EP0723460A4 (fr) 1998-09-30

Family

ID=22447805

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94930498A Withdrawn EP0723460A4 (fr) 1993-10-01 1994-09-28 Therapie genique concernant le systeme nerveux

Country Status (4)

Country Link
EP (1) EP0723460A4 (fr)
JP (1) JPH09505561A (fr)
CA (1) CA2171109A1 (fr)
WO (1) WO1995009654A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1369487A3 (fr) 1994-08-16 2004-04-07 Crucell Holland B.V. Vecteurs récombinants dérivés d'Adenovirus pour la thérapie genique
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
EP0961830A1 (fr) * 1997-01-29 1999-12-08 Neurosearch A/S VECTEURS D'EXPRESSION ET PROCEDES D'EXPRESSION $i(IN VIVO) DE POLYPEPTIDES THERAPEUTIQUES
CN1263854C (zh) 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
CA2323067A1 (fr) * 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Cellules productrices pour virus aptes a la replication utilisees dans le traitement de la malignite
EP2261352A3 (fr) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
JP2003518363A (ja) 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． 保存されたナイセリア抗原
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
GB9924981D0 (en) 1999-10-21 1999-12-22 Univ Manchester Gene therapy
GB2397063A (en) * 1999-10-21 2004-07-14 Cedars Sinai Medical Center A medicament comprising a cytotoxic pro drug activated by HSV TK
RU2281956C2 (ru) 1999-10-29 2006-08-20 Чирон С.Р.Л. Антигенные пептиды neisseria
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
DK1328543T3 (da) 2000-10-27 2009-11-23 Novartis Vaccines & Diagnostic Nukleinsyrer og proteiner fra streptococcus-gruppe A & B
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
CN100515494C (zh) 2001-12-12 2009-07-22 启龙有限公司 抗沙眼衣原体的免疫
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
EP2338524B1 (fr) 2004-08-12 2013-05-22 Cedars-Sinai Medical Center Thérapie génique combinée destinée au traitement de gliomes macroscopiques
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
WO2008095027A2 (fr) 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Vecteur adenoviral comprenant une thymidine kinase de virus herpes simplex virus type 1 et un transgene pour augmenter l'expression du transgene
EP3024497B1 (fr) * 2013-07-26 2021-01-13 University of Iowa Research Foundation Procédés et compositions pour traiter des maladies du cerveau
EP4208718B1 (fr) 2020-09-02 2025-04-16 Johansson Swartling, Fredrik Prédiction de rechute de cancer et traitement de maladies cancéreuses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2051288C (fr) * 1990-09-14 2002-02-05 Robert L. Martuza Destruction ciblee de cellules neoplasiques par un virus
US5529774A (en) * 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BREAKEFIELD ET AL: "GENE TRANSFER INTO THE NERVOUS SYSTEM", MOLECULAR NEUROBIOLOGY, vol. 1, 1987, pages 339 - 371, XP002072764 *
MURASZKO ET AL: "PHARMACOKINETICS AND TOXICOLOGY OF IMMUNOTOXINS ADMINISTERED INTO THE SUBARACHNOID SPACE IN NONHUMAN PRIMATES AND RODENTS", CANCER RESEARCH, vol. 53, 1993, pages 3752 - 3757, XP002072533 *
RAM ET AL: "INTRATHECAL GENE THERAPY FOR MALIGNANT LEPTOMENINGEAL NEOPLASIA", CANCER RESEARCH, vol. 54, 15 April 1994 (1994-04-15), pages 2141 - 2145, XP002072534 *
See also references of WO9509654A1 *

Also Published As

Publication number Publication date
JPH09505561A (ja) 1997-06-03
CA2171109A1 (fr) 1995-04-13
WO1995009654A1 (fr) 1995-04-13
EP0723460A1 (fr) 1996-07-31

Similar Documents

Publication Publication Date Title
EP0723460A4 (fr) Therapie genique concernant le systeme nerveux
DE69529857D1 (de) Strahlentherapie-System
EP0789592A4 (fr) Therapie oculaire genique
DE69419172D1 (de) Elektrodenanordnung für katheter
DE59702969D1 (de) Stabilisatorkombination für das Rotomolding-Verfahren
DE69531544D1 (de) Kathetersystem
DE69536007D1 (de) Kathetersystem
NO953838D0 (no) Fjernbart medisinsk elektrodesystem
FI971557A7 (fi) Latausjärjestelmä
IL108908A0 (en) Speech therapy system
DE69101482D1 (de) System für das seitliche Ausrichten von Bögen.
DE69515305D1 (de) Persönliches feuerwaffensystem
EP0612529A3 (fr) Agent thérapeutique pour NIDDM.
DE69517315D1 (de) Telemetriesystem
FI956046L (fi) Jouhinsegmentti
EP0786999A4 (fr) Procede combine de traitement de l'acne
FI930522A0 (fi) Kaasunkeräysyksikkö
GB9310441D0 (en) Gene therapy
ITTO940379A0 (it) Sequenze specifiche per il dna umano.
FI972408A7 (fi) Tietokoneohjattu järjestelmä
KR950032251U (ko) 사우나용 찜질방 구조
ES1023811Y (es) Aposito terapeutico.
FI940448A0 (fi) Styrsystem
GB9418696D0 (en) Gene therapy
DK134093D0 (da) Bogformet planlaegningssystem

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960318

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980818

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970203